We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
PURITAN MEDICAL

Download Mobile App




Buruli Ulcer Diagnosed by Fluorescent Thin Layer Chromatography

By LabMedica International staff writers
Posted on 29 Nov 2015
Mycobacterium ulcerans infection, known as Buruli ulcer, is a disease of the skin and subcutaneous tissues which is an important but neglected tropical disease with its major impact in rural parts of West and Central Africa where facilities for diagnosis and management are poorly developed. More...


Since prevention is not possible in the absence of either an effective vaccine or a clear understanding of the mode of transmission, a major control strategy for Buruli ulcer is early detection and treatment, hinging on effective laboratory confirmation of suspected cases. Standard routine laboratory techniques for the confirmation of Buruli ulcer disease are M. ulcerans isolation by culture, histopathology, smear microscopy for acid-fast bacilli (AFB) and polymerase chain reaction (PCR).

A team of international scientists led by those at Kwame Nkrumah University of Science and Technology (KNUST) (Kumasi, Ghana) recruited patients from Buruli ulcer treatment centers from January 2014 to June 2014 in Benin, DR Congo, Ghana and Côte d’Ivoire if they had a skin lesion suspected to be caused by M. ulcerans infection. Samples were collected by fine needle aspiration (FNA) or swab according to whether the lesion was non-ulcerated or ulcerated respectively and by biopsy if obtained at surgery. If PCR for the M. ulcerans repeat sequence IS2404 was positive they were included as Buruli ulcer disease patients and if the PCR was negative they were included in the control group.

The team evaluated fluorescent thin layer chromatography (f-TLC) for detection of mycolactone in the laboratory using samples from patients with Buruli ulcer and patients with similar lesions that gave a negative result on PCR. The f-TLC used was a modification of an existing methodology. The TLC plates were placed on an ultra violet lamp with a 365 nm filter. The fluorescent band at retention factor 0.23 from the patient sample was compared to that of the standards to confirm the presence of mycolactone. Two readers were made to confirm the mycolactone test result before test result reporting and were blinded to the PCR test result.

There were 71 IS2404 PCR positive samples and 28 PCR negative samples which were used as controls. The scientists found that mycolactone can be detected in 73% of M. ulcerans infected samples by fluorescent thin layer chromatography. The technique was easy to perform and the result could be read within one hour. The sensitivity was higher than that of microscopy (30–60%) or culture (35%–60%) and compared favorably with that of histology (82%). There was no difference in sensitivity when FNA and swabs were compared although the number of FNA samples was small.

The authors concluded that that mycolactone can be detected from M. ulcerans infected skin tissue by f-TLC technique. The technique is simple, easy to perform and read with minimal costs. In this study it was undertaken by a member of the group from each endemic country. It is a potentially implementable tool at the district level after evaluation in larger field studies. The study was published on November 19, 2015, in the journal Public Library of Science Neglected Tropical Diseases.

Related Links:

Kwame Nkrumah University of Science and Technology 



New
Gold Member
Blood Gas Analyzer
Stat Profile pHOx
3-Part Differential Hematology Analyzer
Swelab Alfa Plus Sampler
New
Celiac Disease Test
Anti-Gliadin IgG ELISA
New
Silver Member
Fibrinolysis Assay
HemosIL Fibrinolysis Assay Panel
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








DIASOURCE (A Biovendor Company)

Channels

Molecular Diagnostics

view channel
Image: New research brings hope for improved early detection of pancreatic cancer (Photo courtesy of Adobe Stock)

New Biomarker Panel to Enable Early Detection of Pancreatic Cancer

Pancreatic cancer (PC) has one of the worst prognoses globally, with only 13% of diagnosed patients surviving for five years or more. In Ireland, there are about 900 cases of pancreatic cancer annually,... Read more

Hematology

view channel
Image: CitoCBC is the world first cartridge-based CBC to be granted CLIA Waived status by FDA (Photo courtesy of CytoChip)

Disposable Cartridge-Based Test Delivers Rapid and Accurate CBC Results

Complete Blood Count (CBC) is one of the most commonly ordered lab tests, crucial for diagnosing diseases, monitoring therapies, and conducting routine health screenings. However, more than 90% of physician... Read more

Immunology

view channel
Image: An “evolutionary” approach to treating metastatic breast cancer could allow therapy choices to be adapted as patients’ cancer changes (Photo courtesy of 123RF)

Evolutionary Clinical Trial to Identify Novel Biomarker-Driven Therapies for Metastatic Breast Cancer

Metastatic breast cancer, which occurs when cancer spreads from the breast to other parts of the body, is one of the most difficult cancers to treat. Nearly 90% of patients with metastatic cancer will... Read more

Pathology

view channel
Image: A real-time trial has shown that AI could speed cancer care (Photo courtesy of Campanella, et al., Nature Medicine)

AI Accurately Predicts Genetic Mutations from Routine Pathology Slides for Faster Cancer Care

Current cancer treatment decisions are often guided by genetic testing, which can be expensive, time-consuming, and not always available at leading hospitals. For patients with lung adenocarcinoma, a critical... Read more

Technology

view channel
Image: Researchers Dr. Lee Eun Sook and Dr. Lee Jinhyung examine the imprinting equipment used for nanodisk synthesis (Photo courtesy of KRISS)

Multifunctional Nanomaterial Simultaneously Performs Cancer Diagnosis, Treatment, and Immune Activation

Cancer treatments, including surgery, radiation therapy, and chemotherapy, have significant limitations. These treatments not only target cancerous areas but also damage healthy tissues, causing side effects... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.